WEBULL
WebtradeDownload

Mirum Pharmaceuticals (MIRM) Following Rare Disease Growth Narrative Looks Undervalued

Simply Wall St · 2d ago

The latest focus on new liver cirrhosis therapies has put Mirum Pharmaceuticals (MIRM) in the spotlight, as its Volixibat candidate features among emerging drugs being tracked across this developing treatment market.

See our latest analysis for Mirum Pharmaceuticals.

Despite the spotlight on Volixibat, Mirum Pharmaceuticals' share price has softened recently, with a 30 day share price return of down 14.43% and a 7 day share price return of down 3.12%. However, the 1 year total shareholder return of 34.69% and very large 5 year total shareholder return show longer term holders have seen strong gains overall.

If this kind of biotech story has your attention, it can be useful to look across the sector and see what else is emerging through the 40 healthcare AI stocks

Bulls argue Mirum Pharmaceuticals' pullback sits at odds with its rare disease portfolio and revenue growth, while bears point to ongoing losses and clinical risk. Which side does the current valuation appear to favor next?

Most Popular Narrative: 32.9% Undervalued

Mirum Pharmaceuticals last closed at $96.72 compared with a narrative fair value estimate of $144.15, which frames the current pullback against a higher implied worth.

The expanding addressable patient population for Mirum's therapies, especially with the increased recognition and diagnosis of later-onset PFIC through broader use of genetic testing and heightened disease awareness, is driving higher-than-expected patient volumes. This growing patient base is expected to directly contribute to sustained top-line revenue growth.

Read the complete narrative.

Want to see what is behind that growth story for Mirum Pharmaceuticals? The narrative focuses on rising rare disease revenue, improving margins, and an earnings profile that depends on ambitious long term forecasts. Curious which assumptions really carry that $144.15 fair value?

Result: Fair Value of $144.15 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Mirum Pharmaceuticals still carries meaningful risk if Livmarli underperforms expectations or if pressures on rare disease drug pricing reduce the earnings power that analysts are building into their models.

Find out about the key risks to this Mirum Pharmaceuticals narrative.

Next Steps

The split sentiment around Mirum Pharmaceuticals, with both risks and rewards in play, makes this a moment to move quickly and test the story against hard data for yourself. To weigh the upside against the concerns in a structured way, start with the 3 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Mirum Pharmaceuticals?

If you like the rare disease story around Mirum Pharmaceuticals, do not stop your research here. Use the Simply Wall St Screener to compare other opportunities and pressure test your portfolio decisions.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.